TDMS Study 96020-01 Pathology Tables
NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Date: 03/03/04
Route: GAVAGE Time: 13:19:18
31 WEEK SSAC FINAL #1
Facility: Battelle Columbus Laboratory
Chemical CAS #: TEFBINARYMIX
Lock Date: 03/27/02
Cage Range: All
Reasons For Removal: 25017 Scheduled Sacrifice
Removal Date Range: 04/14/99 - 04/15/99
Treatment Groups: Include 001 0 NG / 0 UG
Include 004 300 NG /100 UG
Include 005 300 NG /300 UG
Include 006 300 NG /3000 UG
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Date: 03/03/04
Route: GAVAGE Time: 13:19:18
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 300 NG / 300 NG / 300 NG /
0 UG 100 UG 300 UG 3000 UG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 98 80 98 80
Scheduled Sacrifice 16 10 16 10
Early Deaths
Survivors
Animals Examined Microscopically 10 10 10 10
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (1)
Periesophageal Tissue, Pigmentation 1 (100%)
Liver (10) (10) (10) (10)
Eosinophilic Focus, Multiple 3 (30%)
Fatty Change, Diffuse 1 (10%) 7 (70%)
Inflammation 10 (100%) 10 (100%) 10 (100%) 10 (100%)
Mixed Cell Focus 1 (10%) 2 (20%) 3 (30%) 2 (20%)
Mixed Cell Focus, Multiple 1 (10%) 3 (30%)
Necrosis 1 (10%)
Pigmentation 10 (100%) 10 (100%) 8 (80%)
Toxic Hepatopathy 3 (30%)
Bile Duct, Hyperplasia 1 (10%) 1 (10%)
Bile Duct, Inflammation, Chronic Active,
Focal 1 (10%)
Hepatocyte, Hypertrophy 10 (100%) 10 (100%) 10 (100%)
Pancreas (10) (10) (10) (10)
Basophilic Focus 1 (10%)
Inflammation, Chronic Active 1 (10%) 2 (20%) 1 (10%)
Acinus, Atrophy 1 (10%) 1 (10%) 1 (10%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
None
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (10) (10) (10) (10)
Hyperplasia 1 (10%) 1 (10%)
Hypertrophy 3 (30%) 5 (50%) 4 (40%) 2 (20%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 2
NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Date: 03/03/04
Route: GAVAGE Time: 13:19:18
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 300 NG / 300 NG / 300 NG /
0 UG 100 UG 300 UG 3000 UG
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - CONT
Thyroid Gland (10) (10) (10) (10)
Follicular Cell, Hypertrophy 6 (60%) 7 (70%) 10 (100%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (10) (10) (10) (10)
Atrophy 6 (60%) 8 (80%) 10 (100%) 10 (100%)
Uterus (10) (10) (10) (10)
Inflammation, Suppurative 1 (10%)
Metaplasia, Squamous 6 (60%) 8 (80%) 9 (90%) 9 (90%)
Vagina (10) (10)
Inflammation, Suppurative 1 (10%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Spleen (10) (10)
Pigmentation 10 (100%) 10 (100%)
Thymus (10) (10) (10) (10)
Atrophy 6 (60%) 6 (60%) 7 (70%) 6 (60%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
None
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 3
NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Date: 03/03/04
Route: GAVAGE Time: 13:19:18
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 300 NG / 300 NG / 300 NG /
0 UG 100 UG 300 UG 3000 UG
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (10) (10) (10) (10)
Hemorrhage 1 (10%)
Infiltration Cellular, Histiocyte 2 (20%) 1 (10%) 2 (20%)
Inflammation 2 (20%)
Inflammation, Granulomatous 1 (10%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
None
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
None
a Number of animals examined microscopically at site and number of animals with lesion
Page 4
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------